BR112015032554A8 - moduladores do receptor de bradicinina e seu uso - Google Patents

moduladores do receptor de bradicinina e seu uso

Info

Publication number
BR112015032554A8
BR112015032554A8 BR112015032554A BR112015032554A BR112015032554A8 BR 112015032554 A8 BR112015032554 A8 BR 112015032554A8 BR 112015032554 A BR112015032554 A BR 112015032554A BR 112015032554 A BR112015032554 A BR 112015032554A BR 112015032554 A8 BR112015032554 A8 BR 112015032554A8
Authority
BR
Brazil
Prior art keywords
receptor modulators
bradykinin receptor
bradykinin
âbradykinin
useâ
Prior art date
Application number
BR112015032554A
Other languages
English (en)
Other versions
BR112015032554A2 (pt
Inventor
Ribeiro Chagas Jair
Original Assignee
Sepia Pesquisa E Desenvolvimento
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepia Pesquisa E Desenvolvimento filed Critical Sepia Pesquisa E Desenvolvimento
Publication of BR112015032554A2 publication Critical patent/BR112015032554A2/pt
Publication of BR112015032554A8 publication Critical patent/BR112015032554A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo da patente de invenã§ã£o para: “moduladores do receptor de bradicinina e seu uso”. esta invenã§ã£o refere-se geralmente a novos peptã­deos biolã³gicos e purificadas, como os moduladores de receptores da bradicinina, para uso no tratamento e/ou prevenã§ã£o de doenã§as inflamatã³rias, dor, hiperalgesia, doenã§as isquãªmicas cardiovasculares e/ou cerebrais, em indivã­duos que dele necessitam.
BR112015032554A 2013-06-25 2014-06-24 moduladores do receptor de bradicinina e seu uso BR112015032554A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH11682013 2013-06-25
PCT/IB2014/001162 WO2014207534A2 (en) 2013-06-25 2014-06-24 Bradykinin receptor modulators and use thereof

Publications (2)

Publication Number Publication Date
BR112015032554A2 BR112015032554A2 (pt) 2017-08-22
BR112015032554A8 true BR112015032554A8 (pt) 2018-01-23

Family

ID=52142768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015032554A BR112015032554A8 (pt) 2013-06-25 2014-06-24 moduladores do receptor de bradicinina e seu uso

Country Status (5)

Country Link
US (1) US9920096B2 (pt)
EP (1) EP3013851A4 (pt)
JP (1) JP2016528192A (pt)
BR (1) BR112015032554A8 (pt)
WO (1) WO2014207534A2 (pt)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4693993A (en) 1985-06-13 1987-09-15 Stewart John M Bradykinin antagonist peptides
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2137367A1 (en) * 1992-06-05 1993-12-23 Amrit K. Judd Peptides having platelet-derived growth factor (pdgf) activity
JPH07330795A (ja) * 1994-06-07 1995-12-19 Toagosei Co Ltd ペプチドおよびモノクローナル抗体
WO1998007746A1 (en) * 1996-08-19 1998-02-26 Universite De Sherbrooke B1-bradykinin receptor antagonists and use thereof
US20020165174A1 (en) * 1997-01-31 2002-11-07 Gill Parkash S. Methods and compositions for antisense VEGF oligonucleotides
JP2001002586A (ja) * 1999-06-21 2001-01-09 Toagosei Co Ltd 重粒子線療法用薬剤
US7045133B2 (en) * 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
DE10141749A1 (de) 2000-08-29 2002-03-14 Max Delbrueck Centrum Mittel zur Beeinflussung der Angiogenese
US7863239B2 (en) * 2005-01-24 2011-01-04 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
WO2010111625A1 (en) * 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US20100305002A1 (en) * 2009-04-27 2010-12-02 Roswell Park Cancer Institute Reagents and Methods for Producing Bioactive Secreted Peptides
EP2568995B1 (en) * 2010-05-14 2016-07-20 Max-Delbrück-Centrum für Molekulare Medizin Therapeutic use of agonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
WO2012088563A1 (en) 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof

Also Published As

Publication number Publication date
EP3013851A4 (en) 2016-12-28
JP2016528192A (ja) 2016-09-15
BR112015032554A2 (pt) 2017-08-22
WO2014207534A3 (en) 2015-04-09
US20160176929A1 (en) 2016-06-23
US9920096B2 (en) 2018-03-20
EP3013851A2 (en) 2016-05-04
WO2014207534A2 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
ECSP14008556A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201491550A1 (ru) Применение связывающего белка нейротрофинового рецептора p75ntr в терапевтических целях
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
PH12014501702A1 (en) Imidazopyrrolidinone compounds
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201001372A1 (ru) Формы рифаксимина и их применение
ECSP11011496A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas
EA201270722A1 (ru) Формы рифаксимина и их применение
IN2014DN06792A (pt)
DOP2016000027A (es) Moduladores benzoimidazol-2-ilpirimidinas del receptor h4 de histamina
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
IN2014MN02056A (pt)
EA201500363A8 (ru) Человеческие анти-vegfr-2/kdr-антитела
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201692051A1 (ru) Арилзамещенные гетероциклилсульфоны
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
BR112015032554A8 (pt) moduladores do receptor de bradicinina e seu uso
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
BR112015002540A2 (pt) eprotirome para uso na prevenção e/ou tratamento de transtornos capilares e composições do mesmo.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.